Melanoma

Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for antiMART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angio-myolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF.

DATASHEETS & SDS

REFERENCES

• Lodding et al. Virchows Arch A Pathol Anat Histopathol 417: 377,
  1990.
• Rochaix, P et al. PNL2, a New Monoclonal Antibody Directed
  against a Fixative-Resistant Melanocyte Antigen. Mod Pathol 2003;
  16(5):481-490.
• J. A. Ramos-Vara and M. A. Miller. Immunohistochemical
  Identification of Canine Melanocytic Neoplasms With Antibodies to
  Melanocytic Antigen PNL2 and Tyrosinase: Comparison With Melan
  A. Veterinary Pathology OnlineFirst, published on September 21,
  2010 as doi:10.1177/0300985810382095.